Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
Journal of Clinical and Experimental Hematopathology · 2023
DOI: 10.3960/jslrt.23017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2023. Verfasst von Masuho Saburi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oita Prefectural Hospital, Oita, Japan. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
- Department of Pathology, Oita Prefectural Hospital, Oita, Japan.
Zitieren
APA
Saburi, M., Sakata, M., Kodama, Y., Uraisami, K., Takata, H., Miyazaki, Y., Wada, J., Urabe, S., & Ohtsuka, E. (2023). Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.23017
Vancouver
Saburi M, Sakata M, Kodama Y, Uraisami K, Takata H, Miyazaki Y, et al. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab. Journal of Clinical and Experimental Hematopathology. 2023. doi:10.3960/jslrt.23017
BibTeX
@article{Saburi2023,
author = {Saburi, Masuho and Sakata, Masanori and Kodama, Yousuke and Uraisami, Keiichi and Takata, Hiroyuki and Miyazaki, Yasuhiko and Wada, Junpei and Urabe, Shogo and Ohtsuka, Eiichi},
title = {Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2023},
doi = {10.3960/jslrt.23017}
}
EUVIMED